M3D Inc. Awarded NSF SBIR Phase I Grant for Advanced Gamma Camera Design

October 18, 2024

NSF Funds M3D's Gamma Camera to Revolutionize Cancer Node Detection

M3D Inc. has secured a $275,000 SBIR Phase I award from the National Science Foundation (NSF) to advance its research on gamma camera designs aimed at improving sentinel lymph node biopsies, particularly in tough-to-navigate head and neck cancer cases.


Surgeons often face a challenge when a lymph node is too close to the tumor. Radiotracers such as Technetium-99 are injected into the tumor during a biopsy to help locate connected lymph nodes. However, in cases where the lymph node is near the tumor, the nearby radiation injection overwhelms traditional detection methods, like Geiger counter pens, making it difficult for surgeons to identify and target impacted lymph nodes accurately.


With this NSF funding, plus $25,000 in matching funds from the state of Michigan, M3D is working on a tungsten-based mask designed to selectively block radiation from the primary tumor while allowing precise imaging of nearby lymph nodes. This solution is optimized to improve accuracy in lymph node detection, reducing the risk of missing critical lymph nodes and improving overall outcomes for patients with cancer.


Ann Arbor-based M3D has built a reputation for its high-resolution 3D CZT (cadmium zinc telluride) gamma cameras, and this project aims to redefine how surgeons handle complex cases in real-time.


In addition to their research efforts, M3D recently launched its first commercial product, the RAVIN CAM, with initial deliveries set for the end of the year. This safety camera will be deployed in hospitals and healthcare facilities to detect and mitigate radiation contamination.


Receiving this highly competitive NSF grant—awarded to fewer than 10% of applicants—recognizes M3D’s leadership in medical imaging and its commitment to creating practical tools that make a real difference in healthcare.

RECENT ARTICLES

MichBio Hiring: Intern, Association Membership & Resource Analytics

April 15, 2025
MichBio seeks a highly motivated individual who can work creatively in a small team environment and assist in data mining, compilation, and research.

Bio Survey Underscores Impacts of Tariffs for Businesses

April 11, 2025
The Biotechnology Innovation Organization (BIO), of which MichBio is a state affiliate recently released the results of a survey of its members, noting that “U.S. Biotechs Sound the Alarm” on tariff impacts. The findings include: Tariffs on European Union and Canadian imports would increase manufacturing costs for 94% and 82% of biotech firms, respectively. 70% of companies anticipate higher manufacturing costs due to tariffs on China. Tariffs on the European Union would force 50% of biotech firms to identify new research and manufacturing partners. More than 50% of biotech firms predict “increased difficulty” in funding and conducting research if EU tariffs are enacted. 80% of biotech firms would need at least 12 months to find alternative suppliers; 44% would need over two years. The survey noted that sudden tariffs would fundamentally punish American companies, threaten vital research projects and imperil United States leadership in biomedical science. Read BIO’s press release , along with an one-pager summarizing the survey results. 

Amid Proposed Cuts, Commission Calls For $15B NIH Support

April 10, 2025
A federal commission, in a new report , is calling for $15 billion in new financing to reinforce the United States’ biotech leadership amid encroaching competition from China. This comes against a backdrop where the Trump Administration has proposed severe cuts to NIH operations and funding. The National Security Commission on Emerging Biotechnology was created by Congress in 2022 to explore how biotechnology advancements could shape the economy and national security. The body quickly focused on China, as that government has gone about gathering Americans’ genetic information and intellectual property in the biotech space and resourcing their cluster’s rapid growth. The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework to protect U.S. biotech intellectual property and bolster drug development, agriculture, and biological weapons defense: Prioritize biotechnology at the national level Mobilize the private sector to get U.S. products to scale Maximize the benefits of biotechnology for defense Out-innovate our strategic competitors Build the biotechnology workforce of the future Mobilize the collective strengths of our allies and partners The report calls for $1 billion to create an investment fund, more than $6 billion for large-scale research challenges, and a build-up of biomanufacturing sites across the country. Also, it calls for new legislation barring companies that work with U.S. national security agencies or health agencies from using certain Chinese biotech suppliers. The commission doesn’t have the power to authorize any changes but can make recommendations and advise members of Congress. BIO issued a statement in support.